These instructions describe the journal’s scope, article types, submission requirements, editorial and ethical policies, and manuscript preparation rules. Authors should identify the appropriate article type before submission and follow both the general requirements and the category-specific reporting guidance. JBCOMS follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE, updated January 2026) and the guidance of the Committee on Publication Ethics (COPE).
1. Aims, Scope and Journal Information
JBCOMS is a peer-reviewed journal of the Brazilian College of Oral and Maxillofacial Surgery dedicated to oral and maxillofacial surgery and traumatology. It publishes original research, literature reviews, case reports, descriptions of surgical techniques and innovations, and letters to the editor.
2. Submission
Submit manuscripts only through the online submission system: https://submit.dentalpress.com.br/index.php/JBCOMS/about/submissions
2.1 Files required
- Cover letter: article type; statement that the work is original and not under consideration elsewhere; any related submissions, prior presentations (e.g., congress abstract, thesis), or preprint (with DOI); disclosure of any use of AI-assisted technologies; confirmation that all authors approved the submission.
- Title page (separate file): titles in English and Portuguese, running title (up to 50 characters), all authors with ORCID iDs and affiliations, corresponding author and contact details, word counts, number of figures and tables, and all declarations listed in Section 7.3 with identifying details (ethics committee name and approval number, funding, acknowledgments).
- Anonymized manuscript: no author names, affiliations, ethics committee identifiers, acknowledgments, or other identifying information in the text, figures, or file properties.
- Figures as separate image files; tables as editable text within the manuscript or as separate Word or Excel files (Section 10).
- Reporting-guideline checklist with manuscript page references (Section 12), and the ethics approval document, trial or protocol registration, and permissions for third-party material, as applicable.
- Disclosure of interests for every author, using the ICMJE disclosure form or the equivalent form in the submission system.
- Supplementary material (e.g., complete search strategies, extraction tables, videos, datasets), when relevant.
2.2 Language
- Manuscripts may be submitted in English, using concise, clear, grammatically correct, formal language without colloquial expressions. Full text in English is encouraged to broaden the readership.
- An English title, abstract, and keywords are mandatory for all articles.
- Professional language editing is recommended when the authors are not fluent in the language of submission.
2.3 Originality, prior publication, and preprints
- Manuscripts must not have been published, in whole or in substantial part, or be under consideration elsewhere. Abstracts presented at scientific meetings and theses or dissertations are not considered prior publication but must be declared.
- Posting a preprint is permitted if it is declared in the cover letter and the preprint DOI is provided. Authors must update the preprint record with the published version.
- All submissions are screened with text-similarity software. Redundant or duplicate publication, text recycling, and undisclosed overlap with the authors’ previous work are handled under Section 9.7.
3. Peer Review and Editorial Process
- All submissions undergo an editorial screening for scope, completeness, ethics documentation, and similarity. The editors may return a manuscript for correction, reclassify it, or decline it without external review.
- Manuscripts that pass screening undergo double-anonymized peer review by at least two independent external reviewers chosen for subject expertise and absence of conflicts of interest. A statistical or methodological review is added when needed.
- Editorial decisions are: accept, minor revision, major revision, or reject. Authors must respond to each reviewer comment in a point-by-point letter. Revised manuscripts may be sent for further review.
- Target time to first decision: 6 weeks. Authors will be notified if a longer period is required.
- Manuscripts authored by an editor, an editorial board member, or a person from the same institution as the handling editor are managed by an editor without a conflict of interest, and the conflicted person has no access to the review process or the decision.
- Reviewers and editors must keep manuscripts confidential, declare conflicts of interest, and must not upload manuscripts or reviewer reports to AI tools that do not guarantee confidentiality.
- Authors may appeal a decision or submit a complaint to the editorial office, with reasons. Appeals and complaints are handled under COPE procedures.
- Corrections, retractions, and expressions of concern follow ICMJE and COPE guidance. Notices are published, linked to the original article, and indexed.
- Accepted manuscripts are copyedited and sent to the corresponding author for proof approval, to be returned within 5 days. A DOI is assigned to every published article.
4. Authorship, Affiliations and Contributorship
Authorship follows the ICMJE criteria. Each author must meet all four:
- substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data; and
- drafting the work or revising it critically for important intellectual content; and
- final approval of the version to be published; and
- agreement to be accountable for all aspects of the work, ensuring that questions about accuracy or integrity are appropriately investigated and resolved.
Contributors who do not meet these criteria (e.g., technical help, general supervision, or funding acquisition alone) are named in the Acknowledgments with their written permission.
- Number of authors. The author list must reflect real contributions. The usual maximum is 8 authors for Original Articles and Literature Reviews, 6 for Technical Notes and Innovations, and 5 for Case Reports. A longer list requires a justification in the cover letter and a complete contribution statement.
- Contribution statement. Describe each author’s contribution using the CRediT taxonomy (https://credit.niso.org/).
- Corresponding author. One author is responsible for communication with the journal, confirms that all authors approved the manuscript and its submission, and completes the required forms.
- ORCID. An ORCID iD (https://orcid.org/) is required for the corresponding author and strongly encouraged for all co-authors.
- Affiliations. Format as: University or Institution – Center / Faculty / Program / Department / Laboratory / Discipline – City – State or Province (when applicable) – Country. List the institution where the work was done.
- Changes to authorship (additions, removals, or reordering) after submission require a written request stating the reason, signed by all authors including the person added or removed, and are not accepted after acceptance except in exceptional cases reviewed by the editors.
- Anonymization. Enter author names and affiliations only in the designated fields of the submission system and on the title page. Do not include identifying information in the anonymized manuscript.
- AI tools cannot be listed as authors (Section 9.10).
5. Article Types at a Glance
Choose the article type that matches the principal contribution of the work. The editors may reclassify a manuscript after screening. Details for each type are in Section 8.
*Main text = Introduction through Conclusions. It excludes the title page, abstracts, keywords, declarations, references, tables, and figure legends. The abstract limit applies separately to each language.
†For systematic reviews, the studies included in the review may be listed in a separate table or supplementary file in addition to this limit.
6. Title, Abstract and Keywords
6.1 Title
- Provide the title in English. The title must be informative and specific, avoid abbreviations, and have no more than 20 words (about 150 characters).
- The title must identify the study design or article type where applicable (e.g., “randomized clinical trial”, “systematic review and meta-analysis”, “case report”, “technical note”). Authors of Literature Reviews must state the review subtype in the title.
- Provide a running title of up to 50 characters on the title page.
6.2 Abstract
- Provide the abstract in English, with the word limit shown in Section 5. It must contain no references, and abbreviations only if standard or defined at first use. All data must also appear in the main text.
- Original Articles: INTRODUCTION/OBJECTIVE, METHODS (design, setting, participants or sample, interventions, main outcome measures), RESULTS (key findings with effect sizes and confidence intervals), and CONCLUSION (including clinical implications when applicable).
- Literature Reviews: INTRODUCTION/OBJECTIVE, METHODS, RESULTS, and CONCLUSION. A narrative review may use an unstructured abstract.
- Technical Notes and Innovations: BACKGROUND, TECHNIQUE, INITIAL EXPERIENCE (when applicable), and CONCLUSION.
- Case Reports: INTRODUCTION, CASE REPORT, and CONCLUSION.
- For randomized trials, systematic reviews, and meta-analyses, follow CONSORT for Abstracts and PRISMA 2020 for Abstracts, respectively.
- Report the registry name and registration number at the end of the abstract for clinical trials and, when registered, for systematic reviews.
6.3 Keywords
7. Manuscript Preparation
7.1 Format
- Submit the manuscript in Word format (.docx), with continuous line numbers and page numbers, 12-point font, double spacing, and 2.5 cm margins. Do not use tracked changes in the initial submission.
- Use the following order: title (English and Portuguese), abstracts and keywords, main text, declarations, references, tables, and figure legends.
- Main sections of the main text are given for each article type in Section 8. Use headings consistently within an article type.
- Define abbreviations at first use and avoid them in the title. Use SI units. Use generic (international nonproprietary) drug names. For devices, materials, and software, give the manufacturer, model or version, city, and country. Use the FDI two-digit notation for teeth.
7.2 Statistics and data reporting
- Describe the study design, sample size justification, statistical methods, handling of missing data and multiple comparisons, and the software and version used.
- Report effect sizes with 95% confidence intervals and exact P values (P < 0.001 as the lowest value). Do not describe a difference as significant without a statistical test. Follow the SAMPL guidelines for statistical reporting when applicable.
7.3 Declarations
After the Conclusions and before the References, include the following declarations, even when the answer is “none”. In the anonymized manuscript, replace identifying details with “[blinded]”.
- Ethics approval and consent (Section 9.1 to 9.3).
- Funding: all sources of support, including grants, equipment, supplies, and manufacturer support, with grant or contract numbers, and the role of the funder in design, analysis, interpretation, writing, and the decision to publish.
- Conflicts of interest (Section 9.5).
- Data availability (Section 9.6).
- Author contributions (CRediT; Section 4).
- Use of AI-assisted technologies (Section 9.10).
- Acknowledgments: contributors who do not meet authorship criteria, with their permission.
8. Types of Manuscripts Accepted
8.1 Original Article
This category includes in vitro and in vivo (animal) research, clinical research (randomized and non-randomized trials, cohort, case-control, and cross-sectional studies), diagnostic accuracy studies, and case series. Systematic reviews and descriptions of techniques must be submitted under their dedicated categories.
- Main sections: Introduction (rationale, with the objective or hypothesis stated at the end), Materials and Methods, Results, Discussion (principal findings, comparison with the literature, strengths and limitations, implications), and Conclusions (supported only by the results).
- Methods must state the design and the reporting guideline followed; setting and dates of recruitment and follow-up; eligibility criteria; interventions in reproducible detail; primary and secondary outcomes defined in advance; sample size calculation; randomization and blinding when applicable; and the statistical analysis.
- Case series (a defined group of patients with descriptive outcomes) are submitted as Original Articles. They must state how patients were selected (consecutive or otherwise), the number treated and excluded, all outcomes and complications, and the follow-up. STROBE is recommended, and PROCESS for surgical case series.
- In vitro studies must describe sample preparation, sample size, randomization, and blinding. CRIS is recommended for in vitro dental studies.
8.2 Literature Review
This category includes systematic reviews with or without meta-analysis, scoping reviews, integrative reviews, and narrative reviews relevant to oral and maxillofacial surgery. Authors must identify the review subtype in the title and in the submission form. A review must present a clear question or purpose, a critical synthesis, and conclusions supported by the methods used. A meta-analysis is a quantitative component of a systematic review and does not replace systematic searching or critical appraisal.
General format
- Main sections: Introduction, Methods, Results or Evidence Synthesis, Discussion, Conclusions. Narrative reviews may use informative thematic headings within the evidence synthesis. State the review type and methods consistently in the abstract and main text.
- Submit an anonymized manuscript; a reporting checklist with manuscript page references; a flow diagram and protocol when applicable; complete search strategies for each database as supplementary material; and figures as separate image files. Tables must remain editable. Supplementary search strategies and extraction tables are excluded from the word limit.
Systematic review and meta-analysis
- Define a focused question and eligibility criteria using PICO, PECO, or another suitable framework. Register the protocol (e.g., PROSPERO or the Open Science Framework) before starting, or explain its absence, and disclose protocol deviations and their timing.
- Report every information source, the date of the last search, the complete search strategy for each database (PRISMA-S), date or language restrictions and their rationale, screening procedures, full-text exclusions, data extraction, and resolution of disagreements. State whether these tasks were performed independently by more than one reviewer.
- Prespecify outcomes and use appropriate risk-of-bias instruments. Present study characteristics, risk-of-bias findings, individual results, synthesis, and certainty of evidence (e.g., GRADE) when appropriate. Submit the PRISMA 2020 checklist and flow diagram and use relevant extensions when applicable (MOOSE for meta-analyses of observational studies).
- For meta-analysis, describe effect measures, the statistical model and its rationale, heterogeneity, handling of missing or dependent data, sensitivity and subgroup analyses, and assessment of publication bias when feasible. Provide forest plots where useful and justify pooling decisions. If pooling is inappropriate, explain why and provide a transparent narrative synthesis.
Scoping review
- Define population, concept, and context, or another suitable framework, and explain the purpose of mapping the evidence. Describe the protocol, eligibility criteria, information sources, complete search strategy, selection, data charting, synthesis, and iterative changes.
- Map the extent, characteristics, concepts, and gaps in the evidence. Submit a PRISMA-ScR checklist, flow diagram, search strategies, and a table of included sources. Critical appraisal is not universally required, but its methods and use must be described if performed. Do not infer comparative clinical effectiveness solely from the volume of publications.
Integrative review
- Explain why evidence from different study designs or sources must be integrated. Specify the question, search, eligibility, selection, extraction, appraisal appropriate to each design, and the explicit method of thematic, conceptual, or other integration.
- Provide a traceable table of included sources and show how each source contributes to the synthesis. Separate empirical findings from the authors’ interpretation and address discordant evidence. The designation “integrative” does not waive reproducible methods. When claiming a comprehensive systematic search, report the corresponding PRISMA items and flow diagram.
Narrative review
- Define the scope, intended audience, purpose, selection principles, information sources, and search update date. State when the search was selective rather than exhaustive and critically compare supporting and conflicting evidence.
- Use a coherent thematic structure rather than a sequence of article summaries. Distinguish established knowledge, uncertainty, and expert interpretation. Do not claim an absence of evidence or rank treatments unless the search and appraisal methods support such claims.
Editorial screening of reviews
A review may be returned for reclassification or methodological correction when the declared subtype does not match the methods, key searches or selection procedures cannot be verified, conclusions exceed the underlying evidence, or the contribution relative to recent reviews is unclear. Completion of a reporting checklist does not, by itself, establish methodological quality.
8.3 Technical Note and Innovation
This category describes a new instrument, device, procedure, digital workflow, or meaningful modification of an established surgical technique. The principal contribution must be the technical advance and its reproducible description. Initial clinical experience may be included, but claims of efficacy or superiority require an appropriate comparative study.
General format
- Main sections: Introduction, Technical Description, Safety and Limitations, Initial Experience (when applicable), Discussion, and Conclusions.
- The title must accurately describe the innovation. If a technically accurate title needs more than 20 words, request editorial approval in the cover letter.
- Figures should prioritize the steps required to understand or reproduce the technique.
Required technical content
- Introduction: identify the clinical or technical problem, the standard approach, the limitation addressed, related techniques, and the precise element that is new. Distinguish an invention from an adaptation or a new application of known technology.
- Technical Description: state indications, contraindications, patient selection when relevant, setting, personnel and training, planning, equipment, manufacturer/model/version, materials, parameters, sequence of steps, decision points, allowable modifications, safety measures, and postoperative care. Use measurements and labeled illustrations so that another qualified team can reproduce the method.
- Safety and Limitations: describe foreseeable complications, mitigation strategies, fallback or conversion to standard care, additional time or resources, the learning curve, sterilization, and the regulatory status of a new device when relevant.
- Initial Experience: when patients are involved, specify the center, dates, eligibility criteria, number treated, changes in the technique across cases, prospectively defined feasibility measures when available, follow-up, all observed adverse events, failures, revisions, and missing outcomes. Do not select only successful illustrative cases.
- Discussion: compare the technique with published alternatives; discuss potential benefits together with costs and risks; identify the stage of innovation; disclose the limitations of early evidence; and describe the evaluation required next. Conclusions must reflect what was demonstrated, such as reproducibility or initial feasibility, without implying proven safety, effectiveness, or superiority.
Ethics, disclosures and reporting
- For human cases, report research ethics approval or a documented determination of exemption by the ethics committee, clinical consent, and written consent for publication of identifiable information or images. For preclinical studies, report the relevant animal ethics approval.
- Disclose patent applications, intellectual property, consulting relationships, royalties, manufacturer support, donated devices, and the sponsor’s role. Distinguish commercially available products from prototypes and state whether technical materials or code can be shared.
- Use the stage-specific IDEAL guidance for surgical innovation when applicable. TIDieR may supplement the intervention description. An observational series with formal outcomes may also require PROCESS or STROBE, depending on the design. Submit completed checklists with page references.
- An optional captioned video may be submitted when movement is essential, but the written description must remain complete.
8.4 Case Report
A case report describes one or a few patients and offers an educational lesson, a new insight, or a rare presentation relevant to clinical practice. It must contain a thorough and detailed case presentation and a substantive discussion of its relevance to clinical practice and research.
- Main sections: Introduction, Case Report, Discussion, and Conclusion. The Case Report section should include the clinical presentation, diagnostic assessment, therapeutic intervention, follow-up and outcomes (including adverse events), a timeline, and the patient’s perspective when available.
- Follow the CARE guideline and submit the checklist.
- Provide written informed consent for publication. Case reports submitted through Plataforma Brasil follow CONEP guidance (Section 9.1).
8.6 Choosing the appropriate article type
A patient’s diagnostic and treatment course with an educational clinical lesson belongs under Case Report. A defined group of patients with descriptive outcomes belongs under Original Article (case series). A formal comparison or hypothesis test belongs under Original Article. When the principal contribution is a reproducible technical step, submit a Technical Note and Innovation. The editor may reclassify a manuscript after screening.
9. Ethics and Research Integrity
JBCOMS follows the ICMJE Recommendations, the COPE guidance, and the Principles of Transparency and Best Practice in Scholarly Publishing. Authors are responsible for the integrity of the work.
9.1 Research with human participants
- Report that the study was approved by an institutional Research Ethics Committee (or equivalent) before it started, and that it complied with the Declaration of Helsinki (current revision) and applicable national regulations.
- In Brazil, studies involving humans must be approved by a Research Ethics Committee in the CEP/CONEP system (Plataforma Brasil), in accordance with CNS Resolutions No. 466/2012 and No. 510/2016. Case reports follow CONEP Circular Letter No. 166/2018-CONEP/SECNS/MS of June 12, 2018. Studies conducted elsewhere need approval from an equivalent institutional or national ethics committee.
- The published declaration must give the name of the committee, the approval number (e.g., CAAE), and the date. In the anonymized manuscript, state only that approval was obtained and omit the committee name. Submit the approval document separately.
- State that informed consent was obtained from participants, or that the committee waived consent and why. A decision that a study is exempt from review must come from the ethics committee, not from the authors.
- Protect participant privacy and personal data in accordance with applicable law (in Brazil, Law No. 13.709/2018, LGPD).
9.2 Consent for publication and identifiable information
- Obtain written consent for publication from every person whose identifiable information, photographs, or radiographs appear in the manuscript, or from a legal guardian. Facial images may remain identifiable even after names have been removed or the eyes covered. Remove identifiers from images and metadata, and submit the consent documents on request.
9.3 Research with animals
- Report approval by an animal ethics committee (in Brazil, the CEUA, under Law No. 11.794/2008 and CONCEA rules), compliance with the applicable guide for the care and use of laboratory animals, and efforts to reduce pain and distress. Follow the ARRIVE 2.0 guidelines and submit the checklist.
9.4 Registration of clinical trials and reviews
- JBCOMS supports the clinical trial registration policies of the World Health Organization and ICMJE. Clinical trials must be registered in a registry accepted by WHO and ICMJE before enrollment of the first participant. Include the registry name and number at the end of the abstract. Resources: WHO International Clinical Trials Registry Platform (https://www.who.int/clinical-trials-registry-platform), the Brazilian Clinical Trials Registry (ReBEC; https://ensaiosclinicos.gov.br/), and https://www.icmje.org/recommendations/.
- Systematic reviews should be registered in a public registry (e.g., PROSPERO) before data extraction begins.
9.5 Conflicts of interest and funding
- Every author must disclose any actual or potential personal, commercial, political, academic, or financial conflict of interest related to the work, for the past 36 months, using the ICMJE disclosure form or equivalent. The manuscript must contain a conflict-of-interest statement, including when there is none.
- Declare all external sources of funding or support, including grants, equipment, supplies, and manufacturer support, with grant or contract numbers, and describe the role of the funder.
- In studies funded or supported by a company, authors must have access to all the data and must not be restricted from analyzing and publishing them. Commercial sponsorship must not influence the content of the article.
9.6 Data availability
- Each article must include a data availability statement that says where the underlying data, analytic code, and materials can be accessed, or why they cannot be shared (e.g., privacy of participants). Deposit in a public repository is encouraged, and datasets must be cited in the reference list.
- Reports of clinical trials must include a data sharing statement in accordance with ICMJE recommendations.
9.7 Research and publication misconduct
- Fabrication, falsification, plagiarism, undisclosed duplicate or redundant publication, improper authorship, manipulation of citations or of peer review, and fraudulent or manipulated images are research misconduct. Alleged misconduct is investigated under COPE flowcharts, and the authors’ institution may be contacted.
- Confirmed misconduct leads to rejection or retraction of the article and may lead to notification of the institution and a ban on future submissions.
9.8 Image integrity
- Do not enhance, obscure, move, remove, or add features to an image. Adjustments of brightness, contrast, or color are acceptable only if applied to the entire image and if they do not hide or alter information. Disclose any digital processing. The editors may request the original image files.
9.9 Copyright, license and permissions
- Authors retain copyright in their articles. Published content is made available under the Creative Commons Attribution 4.0 International license (CC BY 4.0), which permits sharing and adaptation provided that appropriate credit is given and any changes are indicated.
- Original or modified figures, illustrations, and tables reproduced from copyrighted material must be accompanied by written permission from the rights holder, and the legend must credit the original source. Authors are responsible for obtaining permissions.
9.10 Use of artificial intelligence and AI-assisted technologies
- Authors may use AI-assisted technologies to improve the readability, grammar, and language of the manuscript. Authors must not use them to generate a manuscript without appropriate human intellectual contribution, or to fabricate, falsify, or manipulate data, images, or references.
- Disclosure. Report any use of AI-assisted technologies, in the cover letter and in a statement in the manuscript (Methods or Acknowledgments), naming the tool, its version, the developer, and the purpose of use. Use of AI in data collection, analysis, or figure generation must be described in the Methods.
- Responsibility. All AI-assisted content must remain under human oversight. Authors must review and edit the output, and verify every statement and every reference, because AI systems can produce inaccurate, incomplete, biased, or fabricated information. The authors are fully responsible for the integrity, accuracy, originality, and content of the work.
- Authorship. AI tools cannot be listed as authors or co-authors and cannot be cited as authors. All human authors must meet the authorship criteria in Section 4, approve the final manuscript, agree to its submission, and ensure that the work does not infringe third-party rights.
- Images. Images and figures must not be generated or altered with generative AI, unless this is part of the research method and is described in the Methods.
- Reviewers and editors must follow the confidentiality rules in Section 3.
9.11 Sex, gender and inclusive language
- JBCOMS supports accurate, inclusive, and unbiased scientific reporting. Follow the Sex and Gender Equity in Research (SAGER) guidelines and distinguish sex from gender rather than using the terms interchangeably.
- Sex generally refers to biological attributes, whereas gender refers to socially constructed roles, behaviors, expressions, and identities. When sex or gender is measured or included as a study variable, define how it was determined, measured, or coded and explain its relevance to the research question. Report whether and how sex or gender influenced study design, data collection, analysis, interpretation, or presentation, or state when they are not relevant.
- Use inclusive language throughout the manuscript and avoid bias, stereotypes, and unsupported assumptions about individuals or groups.
10. Illustrations
Number figures, tables, and charts consecutively with Arabic numerals in the order of citation, and cite each one in the text. The maximum number allowed for each article type is shown in Section 5. Indicate the approximate position of each figure and table in the manuscript.
10.1 Figures
- Submit each figure as a separate file in TIFF or high-quality JPG (minimal compression), at least 7 cm wide and 300 dpi at final size. Charts and line drawings should be 600 dpi or more, or in a vector format (PDF, SVG, or EPS).
- Include a clear and concise legend for each figure in the manuscript. Define abbreviations, symbols, and scale bars in the legend.
- Credit the original source in the legend when a figure has been previously published, and attach the permission (Section 9.9).
- Clinical photographs and radiographs must not allow identification of the patient without written consent (Section 9.2). Follow Section 9.8 for image processing.
10.2 Charts and cephalometric tracings
- Cite charts and cephalometric tracings in the text as figures.
- Submit the editable original files produced by the software used to create the chart or tracing. Submission solely as a non-editable bitmap image is not recommended.
- The production team may redraw a chart or tracing for style only, without changing data or content. The authors will approve the result at the proof stage.
10.3 Tables
- Tables must be self-explanatory and complement rather than duplicate the text. They should present numerical or statistical information in a form that supports comparison. Provide a brief, informative title for each table.
- Do not use vertical lines. Use horizontal lines only at the top of the table, below the column headings, and at the bottom.
- Define abbreviations, units, statistical tests, and symbols in a footnote. Do not leave data cells blank: use a dash for a value that does not exist and an ellipsis for unavailable or unknown data, and explain the convention in a footnote.
- When a table has been previously published, include a footnote crediting the original source and attach the permission.
- Submit tables as editable text in Word or Excel, not as images.
11. References
- Cite every work in the reference list in the text, and list every work cited. Identify references in the text with superscript Arabic numerals in the order of first citation. Cite references in tables and figure legends in the same sequence.
- Format references according to the ICMJE and National Library of Medicine style (Vancouver; “Citing Medicine”, https://www.ncbi.nlm.nih.gov/books/NBK7256/). List all authors when there are six or fewer; when there are more than six, list the first six followed by “et al.”.
- Abbreviate journal titles as in the NLM Catalog (https://www.ncbi.nlm.nih.gov/nlmcatalog).
- Include the DOI for every reference that has one, in the form doi:10.xxxx/xxxxx.
- Prefer primary and recent sources. Do not cite retracted articles (unless the citation is to the retraction), unpublished data, or personal communications. Preprints may be cited if labeled as such. Authors are responsible for the accuracy and completeness of references, and the editors may check them.
Reference examples
Journal article, up to six authors: Espinar-Escalona E, Ruiz-Navarro MB, Barrera-Mora JM, Llamas-Carreras JM, Puigdollers-Pérez A, Ayala-Puente J. True vertical validation in facial orthognathic surgery planning. J Clin Exp Dent. 2013;5(5):e231-8. doi:10.4317/jced.51188
Journal article, more than six authors: Pagnoni M, Amodeo G, Fadda MT, Brauner E, Guarino G, Virciglio P, et al. Juvenile idiopathic/rheumatoid arthritis and orthognathic surgery without mandibular osteotomies in the remittent phase. J Craniofac Surg. 2013;24(6):1940-5. [add DOI]
Book: Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. White Plains (NY): March of Dimes Education Services; 2001.
Book chapter: Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.
Thesis or dissertation: Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.
Online document or website: Cancer-Pain.org [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: http://www.cancer-pain.org/
Dataset: cite the dataset with its authors, title, repository, version, year, and persistent identifier (DOI).
12. Reporting Guidelines and Clinical Trial Registration
Authors must follow the reporting guideline appropriate to the study design and submit the completed checklist with manuscript page references. Reporting guidelines improve transparency but do not replace sound methodology. The full list is maintained by the EQUATOR Network (https://www.equator-network.org/).
Clinical trial registration. The registration policy is described in Section 9.4. Include the registration name and identification number at the end of the abstract.
13. Key Resources
14. Before You Submit
Confirm that:
- the article type is correct and the word, reference, figure, and table limits are respected;
- titles, abstracts, and keywords are provided in English and Portuguese, with MeSH and DeCS terms;
- the manuscript is anonymized and a separate title page is provided;
- the reporting-guideline checklist is completed;
- ethics approval, consent, trial or review registration, and permissions are documented;
- the declarations on funding, conflicts of interest, data availability, author contributions, and AI use are included;
- all references are cited, formatted in Vancouver style, and include DOIs;
- figures meet the technical requirements and tables are editable.
Editorial Contact
Dr. Rafaela Scariot, Editor-in-Chief, Journal of the Brazilian College of Oral and Maxillofacial Surgery. E-mail: rafaela_scariot@yahoo.com.br